AHL Partners LLP Has $16.67 Million Stake in Medtronic plc (MDT)
AHL Partners LLP grew its stake in shares of Medtronic plc (NYSE:MDT) by 5.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 187,778 shares of the medical technology company’s stock after buying an additional 8,943 shares during the period. Medtronic plc accounts for 0.4% of AHL Partners LLP’s portfolio, making the stock its 12th biggest holding. AHL Partners LLP’s holdings in Medtronic plc were worth $16,665,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently bought and sold shares of MDT. Parkside Financial Bank & Trust lifted its position in shares of Medtronic plc by 22.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after buying an additional 210 shares in the last quarter. BDO Wealth Advisors LLC purchased a new position in shares of Medtronic plc during the 2nd quarter valued at about $103,000. Motco lifted its position in shares of Medtronic plc by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after buying an additional 99 shares in the last quarter. Israel Discount Bank of New York purchased a new position in shares of Medtronic plc during the 1st quarter valued at about $117,000. Finally, Birch Hill Investment Advisors LLC purchased a new position in shares of Medtronic plc during the 1st quarter valued at about $120,000. 81.37% of the stock is currently owned by hedge funds and other institutional investors.
Medtronic plc (NYSE:MDT) opened at $79.49 on Friday. The firm has a market capitalization of $106,580.00, a P/E ratio of 16.88, a PEG ratio of 2.16 and a beta of 1.00. The company has a current ratio of 1.64, a quick ratio of 1.40 and a debt-to-equity ratio of 0.51. Medtronic plc has a 12-month low of $69.35 and a 12-month high of $89.72.
Medtronic plc (NYSE:MDT) last released its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.04. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.44 billion. Medtronic plc had a return on equity of 12.92% and a net margin of 13.75%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS. analysts forecast that Medtronic plc will post 4.7 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 29th were given a $0.46 dividend. This represents a $1.84 annualized dividend and a yield of 2.31%. The ex-dividend date was Thursday, September 28th. Medtronic plc’s dividend payout ratio (DPR) is presently 61.95%.
In other Medtronic plc news, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the transaction, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $78.03, for a total value of $1,248,480.00. The disclosure for this sale can be found here. Insiders sold a total of 172,407 shares of company stock worth $13,974,223 in the last ninety days. 0.31% of the stock is currently owned by corporate insiders.
A number of research analysts have recently weighed in on MDT shares. Jefferies Group LLC lowered their price objective on Medtronic plc from $103.00 to $96.00 and set a “buy” rating on the stock in a research report on Wednesday, August 23rd. Deutsche Bank AG set a $96.00 price target on Medtronic plc and gave the stock a “buy” rating in a report on Monday, July 31st. BidaskClub cut Medtronic plc from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Cowen and Company set a $95.00 price target on Medtronic plc and gave the stock a “buy” rating in a report on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $92.00 price target on shares of Medtronic plc in a report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the company. Medtronic plc has a consensus rating of “Hold” and a consensus target price of $87.88.
Medtronic plc Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT).
Receive News & Ratings for Medtronic plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc and related companies with MarketBeat.com's FREE daily email newsletter.